Cargando…
Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection
Microbiome-based therapeutics are increasingly evaluated as a strategy to reduce recurrent Clostridioides difficile infection (rCDI), with proposed mechanisms including restoration of the microbiota and microbiota-mediated functions, such as bile acid (BA) metabolism. This study reports a quantitati...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865816/ https://www.ncbi.nlm.nih.gov/pubmed/36677428 http://dx.doi.org/10.3390/microorganisms11010135 |
_version_ | 1784875933074718720 |
---|---|
author | Papazyan, Romeo Ferdyan, Nicky Srinivasan, Karthik Gonzalez, Carlos Shannon, William D. Blount, Ken Fuchs, Bryan C. |
author_facet | Papazyan, Romeo Ferdyan, Nicky Srinivasan, Karthik Gonzalez, Carlos Shannon, William D. Blount, Ken Fuchs, Bryan C. |
author_sort | Papazyan, Romeo |
collection | PubMed |
description | Microbiome-based therapeutics are increasingly evaluated as a strategy to reduce recurrent Clostridioides difficile infection (rCDI), with proposed mechanisms including restoration of the microbiota and microbiota-mediated functions, such as bile acid (BA) metabolism. This study reports a quantitative and sensitive assay for targeted metabolomic assessment, and the application of the assay to profile BA composition in a Phase 2 trial of the investigational microbiota-based live biotherapeutic RBX2660 for reduction of rCDI. A liquid chromatography tandem mass spectrometry method was developed to extract and quantify 35 BAs from 113 participant stool samples from 27 RBX2660-treated rCDI participants in the double-blinded, placebo-controlled clinical trial. The results demonstrate a high-confidence assay as represented by sensitivity, linearity, accuracy, and precision. Furthermore, the assay enabled the observation of primary BAs as the dominant BA species at baseline in stool samples from clinical trial participants, consistent with the expected loss of commensals after broad-spectrum antibiotic treatment. After RBX2660 administration, there was a significant drop in primary BAs concurrent with increased secondary BAs that sustained through 24 months post-RBX2660. Taken together, we describe a robust assay that demonstrates altered BA metabolism in rCDI patients treated with RBX2660 administration. |
format | Online Article Text |
id | pubmed-9865816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98658162023-01-22 Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection Papazyan, Romeo Ferdyan, Nicky Srinivasan, Karthik Gonzalez, Carlos Shannon, William D. Blount, Ken Fuchs, Bryan C. Microorganisms Article Microbiome-based therapeutics are increasingly evaluated as a strategy to reduce recurrent Clostridioides difficile infection (rCDI), with proposed mechanisms including restoration of the microbiota and microbiota-mediated functions, such as bile acid (BA) metabolism. This study reports a quantitative and sensitive assay for targeted metabolomic assessment, and the application of the assay to profile BA composition in a Phase 2 trial of the investigational microbiota-based live biotherapeutic RBX2660 for reduction of rCDI. A liquid chromatography tandem mass spectrometry method was developed to extract and quantify 35 BAs from 113 participant stool samples from 27 RBX2660-treated rCDI participants in the double-blinded, placebo-controlled clinical trial. The results demonstrate a high-confidence assay as represented by sensitivity, linearity, accuracy, and precision. Furthermore, the assay enabled the observation of primary BAs as the dominant BA species at baseline in stool samples from clinical trial participants, consistent with the expected loss of commensals after broad-spectrum antibiotic treatment. After RBX2660 administration, there was a significant drop in primary BAs concurrent with increased secondary BAs that sustained through 24 months post-RBX2660. Taken together, we describe a robust assay that demonstrates altered BA metabolism in rCDI patients treated with RBX2660 administration. MDPI 2023-01-05 /pmc/articles/PMC9865816/ /pubmed/36677428 http://dx.doi.org/10.3390/microorganisms11010135 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Papazyan, Romeo Ferdyan, Nicky Srinivasan, Karthik Gonzalez, Carlos Shannon, William D. Blount, Ken Fuchs, Bryan C. Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection |
title | Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection |
title_full | Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection |
title_fullStr | Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection |
title_full_unstemmed | Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection |
title_short | Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection |
title_sort | human fecal bile acid analysis after investigational microbiota-based live biotherapeutic delivery for recurrent clostridioides difficile infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865816/ https://www.ncbi.nlm.nih.gov/pubmed/36677428 http://dx.doi.org/10.3390/microorganisms11010135 |
work_keys_str_mv | AT papazyanromeo humanfecalbileacidanalysisafterinvestigationalmicrobiotabasedlivebiotherapeuticdeliveryforrecurrentclostridioidesdifficileinfection AT ferdyannicky humanfecalbileacidanalysisafterinvestigationalmicrobiotabasedlivebiotherapeuticdeliveryforrecurrentclostridioidesdifficileinfection AT srinivasankarthik humanfecalbileacidanalysisafterinvestigationalmicrobiotabasedlivebiotherapeuticdeliveryforrecurrentclostridioidesdifficileinfection AT gonzalezcarlos humanfecalbileacidanalysisafterinvestigationalmicrobiotabasedlivebiotherapeuticdeliveryforrecurrentclostridioidesdifficileinfection AT shannonwilliamd humanfecalbileacidanalysisafterinvestigationalmicrobiotabasedlivebiotherapeuticdeliveryforrecurrentclostridioidesdifficileinfection AT blountken humanfecalbileacidanalysisafterinvestigationalmicrobiotabasedlivebiotherapeuticdeliveryforrecurrentclostridioidesdifficileinfection AT fuchsbryanc humanfecalbileacidanalysisafterinvestigationalmicrobiotabasedlivebiotherapeuticdeliveryforrecurrentclostridioidesdifficileinfection |